drugset
Drugs / SCY-635
last change Nov 2014 re-read 3 minutes ago

SCY-635

Protein / enzyme biologic targets PPIA via inhibition

Developed for
chronic hepatitis C virus infection · hepatitis C virus infection

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy2 trials
Phase 1 NCT01290965 Comparator Apr 2007 → Dec 2008 chronic hepatitis C virus infection Scynexis, Inc. Completed No outcome recorded
Phase 2 NCT01265511 Comparator Nov 2010 → Oct 2011 hepatitis C virus infection Scynexis, Inc. Completed No outcome recorded

Press releases naming this drug 10 releases

DateIssuerRelease
2014-11-03 Scynexis, Inc. SCYNEXIS, Inc. Enters Into Worldwide Agreement With Waterstone Pharmaceutical for the Development and Commercialization of SCY-635 for Viral Diseases scynexis.com ↗
2013-04-25 Scynexis, Inc. SCYNEXIS Presents SCY-635 Data on HCV at International Liver Congress scynexis.com ↗
2012-11-11 Scynexis, Inc. SCYNEXIS’ Oral SCY-635 Shows Potential as an Immune Acting Antiviral to Augment Current HCV Treatments scynexis.com ↗
2010-04-16 Scynexis, Inc. SCYNEXIS Presents In Vitro Toxicity Study Suggesting that SCY-635 is Unique in the Cyclophilin Inhibitor Class scynexis.com ↗
2010-04-15 Scynexis, Inc. SCYNEXIS' SCY-635 Demonstrates Impressive Barrier to Resistance in HCV Treatment scynexis.com ↗
2010-04-05 Scynexis, Inc. SCYNEXIS Announces Acceptance of Abstracts Related to its Hepatitis C Clinical Candidate, SCY-635, for Presentation at 45th Annual Meeting of the European Association for the Study of the Liver scynexis.com ↗
2009-11-03 Scynexis, Inc. SCYNEXIS' SCY-635 Demonstrates Positive Antiviral Activity in Combination with Approved and Investigational Anti-HCV Agents scynexis.com ↗
2009-10-28 Scynexis, Inc. SCYNEXIS to Present HCV Data on Novel Cyclophilin Inhibitor SCY-635 at AASLD Annual Meeting scynexis.com ↗
2009-01-08 Scynexis, Inc. First Candidate from SCYNEXIS' Novel Cyclophilin Inhibitor Platform, SCY-635, Establishes Proof of Concept in HCV-Infected Adults scynexis.com ↗
2008-11-03 Scynexis, Inc. SCYNEXIS to Present Preclinical HCV Data on Novel Cyclophillin Inhibitor SCY-635 at AASLD Annual Meeting scynexis.com ↗

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as SCY-635 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01265511 ↗
1

NCT01290965 ↗
Action Inhibit “inhibits cyclophilins A and B” PMID 22425702 ↗ Mar 2012
1

“Cyclophilin A inhibitor” CHEMBL1269597 ↗
Modality Protein / enzyme biologic — CHEMBL1269597 ↗
Route Oral “Oral tablets given bid for 28 days” NCT01265511 ↗
Target PPIA “Cyclophilin A inhibitor” CHEMBL1269597 ↗